Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

KINGMAN KIDNEY CLINIC, INC.

UEI: KJ16GECBSNJ5

KINGMAN KIDNEY CLINIC, INC. is a federal contractor, registered under UEI KJ16GECBSNJ5. It has been awarded $200,000 in federal contracts. Primary work spans Kidney Dialysis Centers. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

KJ16GECBSNJ5

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

1

All time

Active

0

Currently performing

Completed

1

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with KINGMAN KIDNEY CLINIC, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for KINGMAN KIDNEY CLINIC, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in KINGMAN KIDNEY CLINIC, INC.'s top NAICS codes and agencies

NAICS: 621492
SLED
Mobile Dialysis Services for Escambia County Corrections
Solicitation # PD 25-26.121
Escambia County is soliciting proposals under solicitation number PD 25-26.121 for a qualified healthcare provider to deliver comprehensive onsite chronic dialysis services for inmates at the Escambia County Corrections Clinic in Pensacola, Florida. The selected contractor will be responsible for providing all necessary clinical personnel, including a Nephrologist and dialysis technicians, as well as all equipment, supplies, medications, and clinical oversight, with the exception of County-provided dialysis recliners. Routine services are required Monday through Friday from 8:00 a.m. to 4:00 p.m., with the capacity to treat an average of two patients simultaneously. Additionally, the contractor must be able to respond to urgent dialysis requests within 12 hours and emergency requests within one hour. To be considered responsive, bidders must be licensed in Florida, possess at least five years of experience in dialysis services, and provide three client references. The evaluation process is points-based, focusing heavily on the vendor's understanding of the scope of work, implementation plan, and additional services, with the final award based on Phase 2 scoring. Proposals must be submitted as a single PDF via the OpenGov e-procurement portal by November 3, 2026, at 9:30 a.m. The contract requires strict adherence to healthcare standards including CMS, HIPAA, and OSHA, as well as specific insurance coverage for general liability, auto liability, and workers compensation. Payments will be administered in accordance with the Local Government Prompt Payment Act of Florida.
Purchasing

POSTED

20 days ago

DEADLINE

in 13 days
View Details
NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding for U.S. small business concerns (SBCs) to conduct research and development of commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants must be for-profit entities located in the U.S., owned more than 50 percent by U.S. citizens or permanent residents, and employ no more than 500 people. The program accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with the latter two being NIH-specific options to accelerate development. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on an overall impact score, considering commercial potential, technical feasibility, and the quality of the commercialization plan. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines; notably, several institutes, including NIAID and NIAMS, do not accept clinical trials under this NOFO. Applicants must maintain active registrations in SAM, possess a Unique Entity Identifier, and comply with cybersecurity incident reporting requirements, including notifying HHS within 48 hours of a discovery.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on establishing technical merit and feasibility, and Phase II advancing the project toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with the latter two being specific to the NIH. Budget limits vary by participating institute, with Phase I awards typically ranging from 400,000 to 700,000 dollars and Phase II awards reaching up to 3,000,000 dollars. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the environment for success. While clinical trials are generally optional, they are prohibited for specific components, including all FDA centers and several NIH institutes such as NIAMS and NIDCR. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. All applications must be submitted electronically, with a final expiration date of April 06, 2027.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details